35,600
-1.25%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ABL Bio
Its shares trade on KOSDAQ under the ticker 298380.KQ. It has been listed since 19 December 2018. In the fiscal year to 31 December 2025, it reported revenue of ₩79.35bn and a net loss of ₩37.81bn. At that date it held total assets of ₩280.93bn and shareholders' equity of ₩154.72bn.
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Dec 2018
- Employees
- 90
- Website
- ablbio.com ↗
Leadership
Pay as last reported
- Mr. Sang Hun LeeChief Executive Officer, Director
- Mr. Jae Cheon LeeChief Financial Officer, Managing Director₩768.0m
- Mr. Jae Ho JungManaging Director
- Mr. Jeong Dae KimManaging Director
- Mr. Jong Hwa WonManaging Director
- Mr. Won Gyu YooManaging Director
- Ms. Jeong Hye ChoiNon-Executive Independent Director
- Mr. Dong Yun KimNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ABL Bio Inc develops therapeutic drugs for immuno-oncology and neurodegenerative diseases in South Korea.
- The company offers anti-angiogenesis antibodies and anti-tumor targeting antibodies for cancer treatment.
- Novel immune cell targeting antibodies and brain disease dual antibodies expand the product portfolio.
Weaknesses
- ABL Bio Inc employs only ninety staff members, limiting operational capacity significantly.
- The company went public on 19 December 2018, indicating a relatively short market history.
- Seongnam headquarters location may restrict access to broader international talent pools compared to major hubs.
Opportunities
- T cell engager bispecific antibodies offer potential growth in complex immunotherapy markets globally.
- Dual immune cell targeting bispecific antibodies address unmet needs in difficult-to-treat cancer types.
- Antibody-drug conjugates provide new avenues for targeted delivery of potent cytotoxic agents.
Threats
- Rapid technological changes in biotechnology require continuous heavy investment in research and development.
- Competitors in the immuno-oncology sector may launch superior therapies before ABL Bio Inc.
- Regulatory hurdles for novel immune cell targeting antibodies could delay market entry significantly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.